Stryker (NYSE: SYK) reported Q4 EPS of $2.49, $0.03 better than the analyst estimate of $2.46. Revenue for the quarter came in at $4.1 billion versus the consensus estimate of $4.11 billion.

"We had an excellent finish to 2019, achieving 8.1% full-year organic sales growth and 13% adjusted EPS gains. This marks our seventh consecutive year of accelerating organic sales growth and is a testament to our talent, culture and durable operating model," said Kevin Lobo, Chairman and Chief Executive Officer. "The performance was balanced across businesses and geographies and positions us well for continued success."

GUIDANCE:

Stryker sees Q1 2020 EPS of $2.05-$2.10, versus the consensus of $2.05.

Stryker sees FY2020 EPS of $9.00-$9.20, versus the consensus of $9.03.

• We expect 2020 organic net sales growth to be in the range of 6.5% to 7.5% and expect adjusted net earnings per diluted share(2) to be in the range of $9.00 to $9.20. We expect adjusted net earnings per diluted share(2) to be in the range of $2.05 to $2.10 in the first quarter. If foreign currency exchange rates hold near current levels, we expect sales and EPS will be nominally impacted in 2020.

For earnings history and earnings-related data on Stryker (SYK) click here.